Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Sep 20;38(9):822-829.
doi: 10.3760/cma.j.cn501225-20220620-00249.

[Clinical effects of pulsed dye laser dynamically combined with triamcinolone acetonide in the treatment of keloids]

[Article in Chinese]
Affiliations
Observational Study

[Clinical effects of pulsed dye laser dynamically combined with triamcinolone acetonide in the treatment of keloids]

[Article in Chinese]
Z N Liu et al. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. .

Abstract

Objective: To explore the clinical effects of pulsed dye laser (PDL) dynamically combined with triamcinolone acetonide (TAC) in the treatment of keloids. Methods: A retrospectively observational study was conducted. From April 2015 to October 2020, 34 keloid patients (46 keloids) who met the inclusion criteria were admitted to Huaihe Hospital of Henan University. The patients were divided into TAC group and dynamic treatment group according to their treatment methods. There were 18 patients (26 keloids) in TAC group, including 8 males and 10 females, aged (30±12) years, who were treated with TAC injection alone. There were 16 patients (20 keloids) in dynamic treatment group, including 6 males and 10 females, aged (26±11) years, who were treated with TAC injection, PDL, or PDL combined with TAC injection according to the Vancouver scar scale (VSS) score before each treatment. Before the first treatment (hereinafter referred to as before treatment) and 12 months after the first treatment (hereinafter referred to as after treatment), the keloids were assessed by VSS, patient and observer scar assessment scale (POSAS), and the effect of keloids on the quality of life of patients was evaluated with dermatology life quality index (DLQI) scale. Twelve months after treatment, the curative effect of keloid was evaluated according to the VSS score and the effective rate was calculated. The first effective time and the cumulative times of TAC injection at the first effective time, the number of follow-up and the occurrence of adverse reactions of keloids within 12 months after treatment were recorded, and the incidence of adverse reactions was calculated. Data were statistically analyzed with paired sample t test, independent sample t test, Wilcoxon rank-sum test, Mann-Whitney U test, chi-square test, and Fisher's exact probability test. Results: The total VSS scores of patients' keloids in TAC group and dynamic treatment group 12 months after treatment were significantly lower than those before treatment (with t values of 7.53 and 8.09, respectively, P<0.01), and the total scores of pigmentation and vascularity in VSS and POSAS, the total POSAS score, and the DLQI scale score were significantly lower than those before treatment (with Z values of -3.71, -4.04, -4.21, -4.11, -3.76, -3.73, -3.92, and -3.93, respectively, P<0.01). The total scores of pigmentation and vascularity in VSS and POSAS of patients' keloids in dynamic treatment group 12 months after treatment were significantly lower than those in TAC group (with Z values of -2.03 and -2.12, respectively, P<0.05). Twelve months after treatment, the effective rate of patients' keloids in dynamic treatment group was significantly higher than that in TAC group (χ2=3.88, P<0.05). The first effective time of patients' keloids in dynamic treatment group was 5.5 (2.0, 6.0) months, which was significantly shorter than 6.0 (2.3, 10.3) months in TAC group (χ2=4.02, P<0.05). The cumulative times of TAC injection at the first effective time of patients' keloids in dynamic treatment group was 3.2±1.7, which was significantly less than 4.2±1.8 in TAC group (t=2.09, P<0.05). The number of follow-up of patients' keloids within 12 months after treatment in dynamic treatment group was significantly more than that in TAC group (t=-2.94, P<0.01), and the total incidence of adverse reactions was lower than that in TAC group but without statistically significant difference (P>0.05). Conclusions: Compared with TAC injection alone, PDL dynamically combined with TAC in the treatment of keloid can shorten the effective time, reduce the number of TAC injection, and improve the patient's compliance and clinical efficacy.

目的: 探讨脉冲染料激光(PDL)动态联合曲安奈德在临床治疗瘢痕疙瘩中的效果。 方法: 采用回顾性观察性研究方法。2015年4月—2020年10月,河南大学淮河医院收治符合入选标准的瘢痕疙瘩患者34例(瘢痕疙瘩46处)。根据采用的治疗方式,将患者分为曲安奈德组与动态治疗组,前一组患者共18例(瘢痕疙瘩26处),其中男8例、女10例,年龄(30±12)岁,仅进行曲安奈德注射治疗;后一组患者共16例(瘢痕疙瘩20处),其中男6例、女10例,年龄(26±11)岁,根据每次治疗前温哥华瘢痕量表(VSS)评分选择是否进行曲安奈德注射、PDL或者PDL联合曲安奈德注射治疗。首次治疗前及首次治疗后(以下简称治疗前与治疗后)12个月,采用VSS、患者与观察者瘢痕评估量表(POSAS)评估瘢痕疙瘩情况,采用皮肤病生活质量指数(DLQI)量表评估瘢痕疙瘩对患者生活质量的影响。治疗后12个月,根据VSS评分进行瘢痕疙瘩疗效评价并计算显效率。记录瘢痕疙瘩首次显效时间、达到首次显效时曲安奈德累计注射次数、治疗后12个月内随访次数与不良反应发生情况并计算不良反应发生率。对数据行配对样本t检验、独立样本t检验、Wilcoxon秩和检验、Mann-Whitney U检验、χ2检验、Fisher确切概率法检验。 结果: 曲安奈德组、动态治疗组患者瘢痕疙瘩治疗后12个月VSS总评分均较治疗前明显降低(t值分别为7.53、8.09,P<0.01),VSS、POSAS中色泽和血管分布总分与POSAS总评分及DLQI量表评分均较治疗前明显降低(Z值分别为-3.71、-4.04、-4.21、-4.11,-3.76、-3.73、-3.92、-3.93,P<0.01);动态治疗组患者瘢痕疙瘩治疗后12个月VSS、POSAS中色泽和血管分布总分均明显低于曲安奈德组(Z值分别为-2.03、-2.12,P<0.05)。动态治疗组患者瘢痕疙瘩治疗后12个月显效率明显高于曲安奈德组(χ2=3.88,P<0.05)。动态治疗组患者瘢痕疙瘩首次显效时间为5.5(2.0,6.0)个月,明显短于曲安奈德组的6.0(2.3,10.3)个月(χ2=4.02,P<0.05)。动态治疗组患者瘢痕疙瘩达到首次显效时曲安奈德累计注射次数为(3.2±1.7)次,明显少于曲安奈德组的(4.2±1.8)次(t=2.09,P<0.05)。动态治疗组患者瘢痕疙瘩治疗后12个月内的随访次数明显多于曲安奈德组(t=-2.94,P<0.01),总不良反应发生率低于曲安奈德组但差异无统计学意义(P>0.05)。 结论: 与单纯曲安奈德注射比较,PDL动态联合曲安奈德治疗瘢痕疙瘩可缩短显效时间,减少曲安奈德注射次数,提高患者依从性与临床疗效。.

PubMed Disclaimer

Conflict of interest statement

利益冲突 所有作者均声明不存在利益冲突

Figures

图 1
图 1
例1动态治疗组患者前胸部表面皮肤毛囊炎后形成瘢痕疙瘩首次治疗前后情况。1A.治疗前, 瘢痕疙瘩明显高于体表, 充血明显;1B.行脉冲染料激光联合曲安奈德注射治疗后1个月, 瘢痕疙瘩厚度变薄, 颜色得到改善;1C.治疗后2个月, 瘢痕疙瘩平整, 颜色改善, 达到显效
图 2
图 2
例2曲安奈德组患者肩背部不明原因所致瘢痕疙瘩首次治疗前后情况。2A.治疗前, 瘢痕疙瘩明显高出体表, 色泽较深;2B.行曲安奈德注射治疗后1个月, 瘢痕疙瘩色泽加深, 厚度变厚;2C.治疗后2个月, 瘢痕疙瘩稍平整, 颜色改善;2D.治疗后7个月, 瘢痕疙瘩颜色改善;2E.治疗后10个月, 瘢痕疙瘩变平整, 颜色淡, 达到显效

Similar articles

Cited by

References

    1. Limandjaja GC, Niessen FB, Scheper RJ, et al. The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol. 2020;8:360. doi: 10.3389/fcell.2020.00360. - DOI - PMC - PubMed
    1. Motoki THC, Isoldi FC, Brito MJA, et al. Keloid negatively affects body image. Burns. 2019;45(3):610–614. doi: 10.1016/j.burns.2018.10.009. - DOI - PubMed
    1. Morelli Coppola M, Salzillo R, Segreto F, et al. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;11:387–396. doi: 10.2147/CCID.S133672. - DOI - PMC - PubMed
    1. Grabowski G, Pacana MJ, Chen E. Keloid and hypertrophic scar formation, prevention, and management: standard review of abnormal scarring in orthopaedic surgery. J Am Acad Orthop Surg. 2020;28(10):e408–e414. doi: 10.5435/JAAOS-D-19-00690. - DOI - PubMed
    1. 中国整形美容协会瘢痕医学分会常务委员会专家组 中国瘢痕疙瘩临床治疗推荐指南. 中国美容整形外科杂志. 2018;29(5):前插3–前插14. doi: 10.3969/j.issn.1673-7040.2018.05.001. - DOI

Publication types

Substances

LinkOut - more resources